{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:24:12Z","timestamp":1776399852415,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["K24HL159246"],"award-info":[{"award-number":["K24HL159246"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01HL131579"],"award-info":[{"award-number":["R01HL131579"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","award":["45 CFR 46.102"],"award-info":[{"award-number":["45 CFR 46.102"]}],"id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rpth.2024.102418","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T06:29:01Z","timestamp":1713940141000},"page":"102418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bleeding risk from anticoagulant thromboprophylaxis in patients with multiple myeloma: a MarketScan analysis"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-2165","authenticated-orcid":false,"given":"Diego","family":"Adrianzen-Herrera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Giorgio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob F.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansour","family":"Gergi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil A.","family":"Zakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela L.","family":"Lutsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102418_bib1","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1080\/10428194.2023.2247513","article-title":"Thrombosis in multiple myeloma: mechanisms, risk assessment and management","volume":"64","author":"Jarchowsky","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.rpth.2024.102418_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","article-title":"Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Gervaso","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.rpth.2024.102418_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2007-976169","article-title":"Hemostatic dysfunction in paraproteinemias and amyloidosis","volume":"33","author":"Zangari","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102418_bib4","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ejca.2010.03.007","article-title":"Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis","volume":"46","author":"Uaprasert","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.rpth.2024.102418_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ajh.26806","article-title":"Thrombosis in multiple myeloma: risk estimation by induction regimen and association with overall survival","volume":"98","author":"Charalampous","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2024.102418_bib6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.rpth.2024.102418_bib7","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102418_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1160\/TH13-02-0140","article-title":"MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs","volume":"110","author":"Leleu","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102418_bib9","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2016.03.006","article-title":"Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - a systematic review","volume":"141","author":"Al-Ani","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102418_bib10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102418_bib11","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2024.102418_bib12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.rpth.2024.102418_bib13","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood.2022015727","article-title":"Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score","volume":"140","author":"Chakraborty","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102418_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102418_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2022.03.001","article-title":"Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: a prospective cohort study","volume":"213","author":"Sayar","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102418_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.19017","article-title":"Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: a systematic review and updated meta-analysis","volume":"203","author":"Costa","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102418_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.6004\/jnccn.2021.7112","article-title":"Optimizing thromboembolism prophylaxis for the contemporary age of multiple myeloma","volume":"20","author":"Baljevic","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.rpth.2024.102418_bib18","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","article-title":"Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","volume":"107","author":"De Stefano","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102418_bib19","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/pds.4180","article-title":"Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database","volume":"26","author":"Palmaro","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rpth.2024.102418_bib20","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/cncr.32682","article-title":"Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis","volume":"126","author":"Chakraborty","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.rpth.2024.102418_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2023.11.021","article-title":"Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: results of a large survey and clinical guidance recommendations from the IFM group","volume":"233","author":"Frenzel","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102418_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.2008.07577.x","article-title":"Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias","volume":"145","author":"Eby","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102418_bib23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1055\/s-0031-1297372","article-title":"Bleeding and thrombosis in multiple myeloma and related plasma cell disorders","volume":"37","author":"Coppola","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102418_bib24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3816\/CLML.2010.n.080","article-title":"Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma","volume":"10","author":"Talamo","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.rpth.2024.102418_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/pds.4711","article-title":"Validating an algorithm for multiple myeloma based\u00a0on administrative data using a SEER tumor registry and medical record review","volume":"28","author":"Brandenburg","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rpth.2024.102418_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/pds.2041","article-title":"Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data","volume":"20","author":"Garg","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rpth.2024.102418_bib27","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.rpth.2024.102418_bib28","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/bjh.15857","article-title":"Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism","volume":"185","author":"Lutsey","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102418_bib29","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.rpth.2024.102418_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00277-019-03860-2","article-title":"The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma","volume":"99","author":"Li","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.rpth.2024.102418_bib31","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.rpth.2024.102418_bib32","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102418_bib33","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.thromres.2015.09.021","article-title":"Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients","volume":"136","author":"Lee","year":"2015","journal-title":"Thromb Res"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T05:32:28Z","timestamp":1722144748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924001079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2475037924001079"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102418","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding risk from anticoagulant thromboprophylaxis in patients with multiple myeloma: a MarketScan analysis","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102418"}}